TY  - JOUR
T1  - Ibrutinib: A comprehensive review of a promising drug
A1  - Akhil Kapoor
A1  - Prakash Singh
A1  - Surender Beniwal
A1  - Mukesh Singhal
A1  - Raj Nirban
A1  - Harvindra Kumar
JF  - Clinical Cancer Investigation Journal
JO  - Clin Cancer Investig J
SN  - 2278-0513
Y1  - 2016
VL  - 5
IS  - 3
DO  - 10.4103/2278-0513.182059
SP  - 203
EP  - 207
N2  - 
Ibrutinib is a recent Food and Drug Administration-approved drug for the treatment of lymphoid malignancies: mantle cell lymphoma and chronic lymphocytic leukemia (CLL). It is a Bruton's tyrosine kinase (BTK) inhibitor which increases the apoptotic susceptibility of malignant lymphocytes and also causes tissue redistribution of lymphocytes. Strong biological rationale makes BTK an ideal target for therapy of CLL and other B-cell malignancies. We are presenting a comprehensive review of this promising drug, highlighting its metabolism, safety profile, trials, and approved uses.
UR  - https://ccij-online.org/article/ibrutinib:-a-comprehensive-review-of-a-promising-drug-575
ER  -